Feed excerpt — reported by STAT News
Investors and doctors are intensely following an experimental therapy positioned to rival Dupixent, the top-selling drug in immunology.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →